HK Stock Market Move | HQVT(01392) rises again by over 10%, and the lightweight edge-side AI solution enters the scenario verification stage.
Haqing Zhiyuan (01392) has risen more than 10% again, and as of the time of writing, it is up 8.39%, priced at HK$17.7, with a trading volume of HK$5.355 million.
HQVT (01392) has risen over 10% again, and as of the time of writing, it is up 8.39%, priced at HKD 17.7, with a trading volume of HKD 5.355 million.
On the news front, recently, HQVT successfully migrated its large model base system, which relies on high-performance computing server platforms, to a lightweight edge AI platform based on NVIDIA Jetson AGX Orin capabilities. This "edge AI platform," built around NVIDIA Jetson AGX Orin, further enhances the applicability of the series capabilities in the application phase, especially for vertical industry clients, making it more effective, reliable, and sustainably persuasive than mere parameters.
It is worth noting that on August 21, the Hang Seng Index Company announced the results of its review, coinciding with the semi-annual review of the Hang Seng Composite Index. CICC published a report indicating that 49 stocks are expected to be included in the Stock Connect program, among which is HQVT. Inclusion in the Stock Connect will help expand the companys investor base and potentially increase liquidity in H-share trading.
Related Articles

LEE & MAN PAPER (02314) announced its interim results, with a profit attributable to shareholders of HKD 1.373 billion, an increase of 69.28% year-on-year.

Hefei Lifeon Pharmaceutical (003020.SZ): Two products are expected to be selected for the national centralized procurement of medicines.

Shandong Keyuan Pharmaceutical (301281.SZ): Two products are expected to be selected in the national centralized drug procurement.
LEE & MAN PAPER (02314) announced its interim results, with a profit attributable to shareholders of HKD 1.373 billion, an increase of 69.28% year-on-year.

Hefei Lifeon Pharmaceutical (003020.SZ): Two products are expected to be selected for the national centralized procurement of medicines.

Shandong Keyuan Pharmaceutical (301281.SZ): Two products are expected to be selected in the national centralized drug procurement.

RECOMMEND





